348 related articles for article (PubMed ID: 27381905)
1. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Königs C; Li R; Lollar P; Meeks SL
Blood; 2016 Oct; 128(16):2055-2067. PubMed ID: 27381905
[TBL] [Abstract][Full Text] [Related]
2. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
[TBL] [Abstract][Full Text] [Related]
3. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.
Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
Blood; 2007 Dec; 110(13):4234-42. PubMed ID: 17848617
[TBL] [Abstract][Full Text] [Related]
4. Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.
Kahle J; Orlowski A; Stichel D; Healey JF; Parker ET; Jacquemin M; Krause M; Tiede A; Schwabe D; Lollar P; Königs C
Blood; 2017 Aug; 130(6):808-816. PubMed ID: 28507083
[TBL] [Abstract][Full Text] [Related]
5. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
Saenko EL; Shima M; Gilbert GE; Scandella D
J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
[TBL] [Abstract][Full Text] [Related]
6. Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor.
Kallas A; Pooga M; Benhida A; Jacquemin M; Saint-Remy JM
Thromb Res; 2002 Sep; 107(6):291-302. PubMed ID: 12565716
[TBL] [Abstract][Full Text] [Related]
7. Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors.
Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
Blood; 2008 Aug; 112(4):1151-3. PubMed ID: 18495957
[TBL] [Abstract][Full Text] [Related]
8. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
9. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.
Wroblewska A; van Haren SD; Herczenik E; Kaijen P; Ruminska A; Jin SY; Zheng XL; van den Biggelaar M; ten Brinke A; Meijer AB; Voorberg J
Blood; 2012 May; 119(22):5294-300. PubMed ID: 22498747
[TBL] [Abstract][Full Text] [Related]
10. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes.
Gilles JG; Lavend'homme R; Peerlinck K; Jacquemin MG; Hoylaerts M; Jorieux S; Mazurier C; Vermylen J; Saint-Remy JM
Thromb Haemost; 1999 Jul; 82(1):40-5. PubMed ID: 10456452
[TBL] [Abstract][Full Text] [Related]
11. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.
Peerlinck K; Jacquemin MG; Arnout J; Hoylaerts MF; Gilles JG; Lavend'homme R; Johnson KM; Freson K; Scandella D; Saint-Remy JM; Vermylen J
Blood; 1999 Apr; 93(7):2267-73. PubMed ID: 10090936
[TBL] [Abstract][Full Text] [Related]
12. A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII.
Eubanks J; Baldwin WH; Markovitz R; Parker ET; Cox C; Kempton CL; Meeks SL
Blood; 2016 Apr; 127(16):2028-34. PubMed ID: 26825708
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice.
Lavigne-Lissalde G; Lacroix-Desmazes S; Wootla B; Tarrade C; Schved JF; Kaveri SV; Granier C; Villard-Saussine S
Thromb Haemost; 2007 Jul; 98(1):138-47. PubMed ID: 17598006
[TBL] [Abstract][Full Text] [Related]
14. Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor.
Ronayne EK; Peters SC; Gish JS; Wilson C; Spencer HT; Doering CB; Lollar P; Spiegel PC; Childers KC
Front Immunol; 2021; 12():697602. PubMed ID: 34177966
[TBL] [Abstract][Full Text] [Related]
15. Role of anti-idiotypic antibodies in immune tolerance induction.
Gilles JG
Haemophilia; 2010 May; 16(102):80-3. PubMed ID: 20536989
[TBL] [Abstract][Full Text] [Related]
16. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies.
Scandella D
Vox Sang; 1999; 77 Suppl 1():17-20. PubMed ID: 10529680
[TBL] [Abstract][Full Text] [Related]
17. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
Yada K; Nogami K; Shima M
Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
[TBL] [Abstract][Full Text] [Related]
18. The diversity of the immune response to the A2 domain of human factor VIII.
Markovitz RC; Healey JF; Parker ET; Meeks SL; Lollar P
Blood; 2013 Apr; 121(14):2785-95. PubMed ID: 23349389
[TBL] [Abstract][Full Text] [Related]
19. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
[TBL] [Abstract][Full Text] [Related]
20. Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.
Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
J Thromb Haemost; 2009 Apr; 7(4):658-64. PubMed ID: 19187078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
